Mont-Saint-Guibert, Belgium, September 4, 2025, 07:00 am CET – regulated information – Celyad Oncology (Euronext: CYAD) (“Celyad” or the “Company”), today announced that 3,849,040 registered shares benefit from a double voting right as of September 4, 2025. As a result, the Company’s total number of voting rights is now 61,335,454.
This information is published in accordance with Article 15 of the Belgian Law of 2 May 2007 on the disclosure of major participations in issuers whose shares are admitted to trading on a regulated market and regarding miscellaneous provisions.
Figures – Modified on September 4, 2025, following the Double Voting Rights:
| Total amount of share capital (EUR) | 9,216,154.53 |
| Total Number of shares with single voting rights | 32,044,490 |
| Total Number of shares with double voting rights | 12,717,415 |
| Total Number of Shares | 44,761,905 |
| Total of voting rights | 57,479,320 |
| Total number of attributed warrants | 3,856,134 |
| Total number of shares with voting rights that could be created following the exercise of the attributed warrants | 3,856,134 |
| Total number of diluted shares (Outstanding shares + Warrants) | 48,618,039 |
| Total number of diluted shares with voting rights | 61,335,454 |
Contact person for regulated information (financial, transparency)
By law, any transparency declaration must be sent to our Company by email to the attention of Matthew Kane, Chief Executive Officer (CEO): investors@celyad.com
Further questions about the content of this release can be sent to investors@celyad.com
